<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cullinan Oncology Llc — News on 6ix</title>
    <link>https://6ix.com/company/cullinan-oncology-llc</link>
    <description>Latest news and press releases for Cullinan Oncology Llc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 10 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cullinan-oncology-llc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683554ac78dffbe2df0e8ffb.webp</url>
      <title>Cullinan Oncology Llc</title>
      <link>https://6ix.com/company/cullinan-oncology-llc</link>
    </image>
    <item>
      <title>Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only</description>
    </item>
    <item>
      <title>Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-fireside-chat-120000742</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-fireside-chat-120000742</guid>
      <pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 11</description>
    </item>
    <item>
      <title>Adimab Reports Strong Partnering Year for 2025</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/adimab-reports-strong-partnering-year-for-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/adimab-reports-strong-partnering-year-for-2025-1</guid>
      <pubDate>Mon, 12 Jan 2026 19:57:00 GMT</pubDate>
      <description>Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-highlights-120000023</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-highlights-120000023</guid>
      <pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
      <description>Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026 Preliminary cash and investments of $439.0</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-showcases-compelling-clinical-153100518</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-showcases-compelling-clinical-153100518</guid>
      <pubDate>Mon, 08 Dec 2025 15:31:00 GMT</pubDate>
      <description>CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-receives-fda-fast-120000943</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-receives-fda-fast-120000943</guid>
      <pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
      <description>Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tr</description>
    </item>
    <item>
      <title>Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-taiho-pharmaceutical-cullinan-120000135</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-taiho-pharmaceutical-cullinan-120000135</guid>
      <pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
      <description>Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced the companies have initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of zipalertinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (e</description>
    </item>
    <item>
      <title>Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EG...</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-eg</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-eg</guid>
      <pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
      <description>Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for</description>
    </item>
    <item>
      <title>Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-upcoming-investor-120000257</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-upcoming-investor-120000257</guid>
      <pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team will participate in two upcoming investor conferences and will host a company event at the 2025 American Society of Hematology (“ASH”) Annual Meeting in Orlando, FL. Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medic</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-reports-120000128</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-reports-120000128</guid>
      <pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
      <description>Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be presented in oral presentation at ASH 2025 Company to share initial data for CLN-978, a CD19xCD3 bispecific T cell engager, in both SLE and RA in first half of 2026 Based on review of emerging clinical data, CLN-619 and CLN-617 programs discontinued Cash and investments of $475.5 million as of Sep</description>
    </item>
    <item>
      <title>Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-showcase-data-demonstrating-141100953</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-showcase-data-demonstrating-141100953</guid>
      <pubDate>Mon, 03 Nov 2025 14:11:00 GMT</pubDate>
      <description>CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically active target doses; initial dose escalation results in 40 patients indicate a manageable safety profile across all doses assessed Company to host in-person event on Monday, December 8, 2025, at 8:00 p.m. ET CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-shares-additional-preclinical-150100717</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-shares-additional-preclinical-150100717</guid>
      <pubDate>Sat, 25 Oct 2025 15:01:00 GMT</pubDate>
      <description>CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, its novel investigational CD19xCD3 bispecific T cell engager. These data will be presented at the American Co</description>
    </item>
    <item>
      <title>Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-cullinan-therapeutics-present-222700393</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-cullinan-therapeutics-present-222700393</guid>
      <pubDate>Sun, 12 Oct 2025 22:27:00 GMT</pubDate>
      <description>Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) or uncommon non-ex20ins EGFR mutations and CNS involvement. Data will be presented at the European Society for Medical</description>
    </item>
    <item>
      <title>Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-fireside-chat-110000223</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-fireside-chat-110000223</guid>
      <pubDate>Fri, 12 Sep 2025 11:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 9:30 a.m. ET. A webcast of the fireside chat will be available under the Events and Presentations</description>
    </item>
    <item>
      <title>Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-cullinan-therapeutics-present-093000287</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-cullinan-therapeutics-present-093000287</guid>
      <pubDate>Tue, 09 Sep 2025 09:30:00 GMT</pubDate>
      <description>Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the REZILIENT1 and REZILIENT2 trials of zipalertinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic non-small cell lung cancer (NSCLC). These data will be presented at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer as mini oral presentations on September 9 during the &quot;MA08 - Common and Uncommon EGFR Mutations,</description>
    </item>
    <item>
      <title>Cullinan Therapeutics to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-upcoming-investor-200500340</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-participate-upcoming-investor-200500340</guid>
      <pubDate>Thu, 21 Aug 2025 20:05:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, NY on Thursday, September 4, 20</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-reports-110000768</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-provides-corporate-reports-110000768</guid>
      <pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
      <description>CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D., and</description>
    </item>
    <item>
      <title>Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-cullinan-therapeutics-announce-110000178</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/taiho-oncology-cullinan-therapeutics-announce-110000178</guid>
      <pubDate>Tue, 22 Jul 2025 11:00:00 GMT</pubDate>
      <description>Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of Lung Cancer&apos;s (IASLC) 2025 World Conference on Lung Cancer (WCLC), to be held September 6-9, 2025, in Barcelona, Spain.</description>
    </item>
    <item>
      <title>Disc Medicine Appoints Nadim Ahmed to its Board of Directors</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/disc-medicine-appoints-nadim-ahmed-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/disc-medicine-appoints-nadim-ahmed-to-its-board-of-directors</guid>
      <pubDate>Mon, 14 Jul 2025 12:30:00 GMT</pubDate>
      <description>WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. “I am excited to welcome Nadim to Disc’s Board of Directors at suc</description>
    </item>
    <item>
      <title>Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases</title>
      <link>https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-licenses-rights-velinotamig-200200416</link>
      <guid isPermaLink="true">https://6ix.com/company/cullinan-oncology-llc/news/cullinan-therapeutics-licenses-rights-velinotamig-200200416</guid>
      <pubDate>Wed, 04 Jun 2025 20:02:00 GMT</pubDate>
      <description>Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on develo</description>
    </item>
  </channel>
</rss>